<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Proposed criteria for measurement of disease progression in adults with chronic myelomonocytic leukemia (CMML) or other myelodysplastic/myeloproliferative neoplasms</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Proposed criteria for measurement of disease progression in adults with chronic myelomonocytic leukemia (CMML) or other myelodysplastic/myeloproliferative neoplasms</h1>
<div class="graphic"><div class="figure"><div class="ttl">Proposed criteria for measurement of disease progression in adults with chronic myelomonocytic leukemia (CMML) or other myelodysplastic/myeloproliferative neoplasms</div><div class="cntnt"><table cellspacing="0"><tbody> <tr class="divider_bottom"> <td><strong>Combination of two major criteria, one major and two minor criteria, or three minor criteria from list</strong></td> </tr> <tr> <td class="subtitle1_single">Major criteria</td> </tr> <tr> <td class="indent1">Increase in blast count*</td> </tr> <tr> <td class="indent2">&lt;5% blasts: ≥50% increase and to &gt;5% blasts</td> </tr> <tr> <td class="indent2">5 to 10% blasts: ≥50% increase and to &gt;10% blasts</td> </tr> <tr> <td class="indent2">10 to 20% blasts: ≥50% increase and to &gt;20% blasts</td> </tr> <tr> <td class="indent2">20 to 30% blasts: ≥50% increase and to &gt;30% blasts<sup>¶</sup></td> </tr> <tr> <td class="indent1">Evidence of cytogenetic evolution<sup>Δ</sup></td> </tr> <tr> <td class="indent2">Appearance of a previously present or new cytogenetic abnormality in complete cytogenetic remission via FISH or classic karyotyping</td> </tr> <tr> <td class="indent2">Increase in cytogenetic burden of disease by ≥50% in partial cytogenetic remission via FISH or classic karyotyping</td> </tr> <tr> <td class="indent1">New extramedullary disease</td> </tr> <tr> <td class="indent2">Worsening splenomegaly</td> </tr> <tr> <td class="indent3">Progressive splenomegaly that is defined by IWG-MRT: The appearance of a previously absent splenomegaly that is palpable at &gt;5 cm below the left costal margin or a minimum 100% increase in palpable distance for baseline splenomegaly of 5 to 10 cm or a minimum 50% increase in palpable distance for baseline splenomegaly of &gt;10 cm</td> </tr> <tr> <td class="indent2">Extramedullary disease outside of the spleen</td> </tr> <tr class="divider_bottom"> <td class="indent3">To include new/worsening hepatomegaly, granulocytic sarcoma, skin lesions, etc</td> </tr> <tr> <td class="subtitle1_single">Minor criteria</td> </tr> <tr> <td class="indent1">Transfusion dependence<sup>◊</sup></td> </tr> <tr> <td class="indent1">Significant loss of maximal response on cytopenias ≥50% decrement from maximum remission/response in granulocytes or platelets</td> </tr> <tr> <td class="indent1">Reduction in Hgb by ≥1.5 g/dL from best response or from baseline as noted on complete blood count</td> </tr> <tr> <td class="indent1">Increasing symptoms as noted by increase in ≥50% as per the MPN-SAF TSS<sup>§</sup></td> </tr> <tr> <td class="indent1">Evidence of clonal evolution (molecular)<sup>¥</sup></td> </tr> </tbody></table></div><div class="graphic_lgnd">The table describes uniform criteria proposed by an international consortium to be used in clinical trials for the measurement of disease progression in adults with chronic myelomonocytic leukemia and other myelodysplastic/myeloproliferative disorders. </div><div class="graphic_footnotes">MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm; IWG-MRT: International Working Group for Myelofibrosis Research and Treatment; FISH: fluorescence in situ hybridization; Hgb: hemoglobin; MPN-SAF TSS: Myeloproliferative Neoplasm Symptom Assessment Form total symptom score.<br/>* Blasts as measured from the bone marrow.<br/>¶ Patients with development of acute myeloid leukemia from MDS/MPN; 20 to 30% blasts may be allowed on some clinical trials for patients with MDS/MPN.<br/>Δ Increase in cytogenetic burden of disease by ≥50% (via FISH or classic karyotyping). Given variability of fluorescent probes used in FISH, cytogenetic normalization via FISH will depend on specific probes used.<br/><font class="lozenge">◊</font> Transfusion dependency is defined by a history of at least 2 units of red blood cell transfusions in the past month for a hemoglobin level &lt;8.5 g/dL that was not associated with clinically overt bleeding. Cytopenias resulting from therapy should not be considered in assessment of progression.<br/>§ MPN-SAF TSS validation among patients with MDS/MPN is currently under way (RA Mesa, personal communication, 2014).<br/>¥ The identification of new abnormalities using single nucleotide polymorphism arrays or sequencing or a clearly significant increase in mutational burden of a previously detected abnormality. Precise criteria for defining new abnormalities and what exactly constitutes a significant increase in mutational burden are open to interpretation; we suggest that this criterion should be used conservatively based on current evidence.</div><div class="graphic_reference">This research was originally published in Blood. Savona MR, Malcovati L, Komrokji R, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood 2015; 125:1857. Copyright © 2015 American Society of Hematology.</div><div id="graphicVersion">Graphic 100627 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
